RPG Life Sciences
1,926.50
-19.40(-1.00%)
Market Cap₹3,186.24 Cr
PE Ratio15.98
IndustryHealthcare
Company Performance:
1D-1.00%
1M-16.50%
6M-15.64%
1Y-11.86%
5Y+357.11%
View Company Insightsright
More news about RPG Life Sciences
17Oct 25
RPG Life Sciences Reports Strong Q2 FY26 Results; CFO Resigns
RPG Life Sciences announced Q2 FY26 results with revenue growth of 5.50% YoY to Rs. 18,168 lakhs. Profit After Tax surged 777.40% to Rs. 3,685 lakhs, boosted by exceptional income from insurance proceeds. EBITDA decreased by 9%. Domestic Formulations contributed 71% to H1 FY26 sales. The company's CFO, Mr. Vishal Shah, resigned effective October 23, 2025. Strategic initiatives include focus on mega brands, ESG, and global expansion.
 no imag found
25Jul 25
RPG Life Sciences Targets ₹500 Crore OTC Market, Reports Q1 Results
RPG Life Sciences announced plans to expand into the ₹500 crore OTC pharmaceutical market in India, investing ₹200 crore in immunosuppressant drugs. The company reported Q1 financial results with revenue of ₹168.90 crore, up 2.1% year-on-year. EBITDA margin slightly decreased to 24.10%, and Profit Before Tax was ₹35.40 crore. Domestic Formulations segment showed strong growth, while International Formulations and API segments faced challenges. The company is focusing on global generics and exploring inorganic growth opportunities.
 no imag found
25Jul 25
RPG Life Sciences Expands Global Reach, Reports Steady Q1 Growth
RPG Life Sciences announced plans to expand its international formulations and API business. Q1 financial results show revenue of ₹168.90 crore, up 2.1% year-over-year, with an EBITDA margin of 24.1%. Domestic formulations contributed 69% to total sales, while international formulations and API business accounted for 19% and 12% respectively. The company is exploring inorganic growth opportunities and has appointed Deepak Shukla as Chief Executive - API Business.
 no imag found
25Jul 25
RPG Life Sciences Reports Q1 FY26 Results, Appoints New API Business Chief
RPG Life Sciences Limited announced its Q1 FY26 financial results, reporting a 2.1% YoY increase in revenue to ₹168.90 crores. The company maintained a healthy EBITDA margin of 24.1% despite a slight decline. Domestic Formulations segment grew by 9.5%, while the API segment saw a 22.4% decline due to a fire incident. The company appointed Mr. Deepak Shukla as Chief Executive - API Business to strengthen this segment. Management remains optimistic about future growth, focusing on new product development, market expansion, and exploring inorganic growth opportunities.
 no imag found
25Jul 25
RPG Life Sciences Reports 2.1% Revenue Growth in Q1 FY26, Maintains Strong EBITDA Margin
RPG Life Sciences Limited announced its Q1 FY26 financial results, showing a 2.1% year-on-year revenue increase to Rs. 168.90 crores. The company maintained a strong EBITDA margin of 24.1%. Domestic Formulations grew by 9.5%, while International Formulations and APIs declined. The company is focusing on inorganic growth, manufacturing capacity expansion, portfolio growth, and digital initiatives. Mr. Deepak Shukla was appointed as Chief Executive - API Business.
 no imag found
29Apr 25
RPG Life Sciences Reports Stellar Q4 FY25 Results: PAT Soars 786%, Announces Special Dividend
RPG Life Sciences Limited announced impressive financial results for Q4 and FY 2024-25. Q4 highlights include a 13% YoY revenue increase to ₹143.09 crore, 41% PBT growth, and a remarkable 786% PAT jump to ₹117.35 crore. Full-year results show 12% revenue growth to ₹653.43 crore and 28% PBT increase. The company reported exceptional items, including a ₹98.93 crore profit from land assignment and a ₹16.33 crore loss from a fire incident. A final dividend of ₹20 and special dividend of ₹4 per share were recommended. The company maintains a strong cash position of ₹266 crore and is exploring inorganic growth opportunities.
 no imag found
28Apr 25
RPG Life Sciences Reports Stellar Q4 Results, Declares Special Dividend Amid Leadership Changes
RPG Life Sciences announced impressive Q4 FY2025 results with net profit soaring to ₹1,173.50 crore, up from ₹132.40 crore in Q4 FY2024. Revenue increased to ₹1,430.90 crore. The company declared a final dividend of ₹20 and a special dividend of ₹4 per equity share. Exceptional items included a ₹1,262.30 crore profit from land assignment and a ₹163.30 crore loss from a fire incident. Key leadership changes were announced, including the appointment of a new Managing Director.
 no imag found
RPG Life Sciences
1,926.50
-19.40
(-1.00%)
1 Year Returns:-11.86%
Industry Peers
Sun Pharmaceutical
1,713.40
(-0.64%)
Divis Laboratories
6,297.50
(+0.22%)
Torrent Pharmaceuticals
4,226.40
(+0.37%)
Cipla
1,328.90
(-1.55%)
Dr Reddys Laboratories
1,282.30
(+0.16%)
Lupin
2,228.70
(+0.09%)
Zydus Life Science
902.40
(-0.84%)
Mankind Pharma
2,039.50
(-1.74%)
Aurobindo Pharma
1,171.40
(+1.02%)
Alkem Laboratories
5,377.00
(-1.59%)